Given that both MDM2 and STAT3 inhibitors have demonstrated promise in preclinical cancer studies, including those involving other hematologic malignancies, combined targeting of these two pathways may offer a more effective and safer treatment approach for ALL. This evidence concerns the gene STAT3 and cancer.